ArticleBritish journal of haematology2026
Stroke burden and functional impacts in adults with sickle cell disease.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke in sickle cell disease (SCD) has been well characterized in children, but data in adults remain insufficient, particularly regarding long-term functional consequences. The objective was to determine lifetime prevalence of symptomatic stroke, followed by characterization of stroke type, aetiology, treatments and functional status at last follow-up. We retrospectively reviewed adults (≥18 years) with any SCD phenotype followed at a tertiary centre from 2011 to 2023. Functional status was assessed using the Montreal Cognitive Assessment (MoCA) and Modified Rankin Scale (mRS). Among 454 adults with all major phenotypes of SCD, median age was 32 years [range 18-79] and 261 (57.5%) were women. At last follow-up, 21 individuals (4.6%) had a confirmed history of symptomatic stroke (median age at stroke onset of 42 years [range 4-68]), including 14 (3.1%) with cerebral infarction (median age 32 years [4-68]) and 7 (1.5%) with intracranial haemorrhage (median age 45 years [20-65]). Stroke was associated with marked long-term impairment, represented by lower MoCA (20.6 (±1.3) vs. 26.1 (±0.2), p < 0.001) and higher mRS (2 [1-3] vs. 0 [0-1], p < 0.001). These findings fill a critical evidence gap and underscore the urgency of targeted prevention and intervention strategies in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.